Hhlr Advisors, Ltd. Argenx Se Transaction History

Hhlr Advisors, Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $701,765 - $1.04 Million	-1,900 Reduced 10.18%	16,765 $8.24 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $6.72 Million - $7.89 Million	18,665 New	18,665 $7.27 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $32.3 Million - $45.5 Million	-120,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $69.9 Million - $83.1 Million	-237,000 Reduced 66.39%	120,000 $36.2 Million
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $4.77 Million - $5.93 Million	-18,540 Reduced 4.94%	357,000 $107 Million
Q1 2021 May 17, 2021	SELL	$268.3 - $380.31 $25.3 Million - $35.9 Million	-94,460 Reduced 20.1%	375,540 $103 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $53.5 Million - $97.7 Million	420,000 Added 840.0%	470,000 $106 Million
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $5.33 Million - $8.21 Million	50,000 New	50,000 $8.03 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.